8,856 Shares in Edwards Lifesciences Corporation $EW Bought by Hilltop National Bank

Hilltop National Bank acquired a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 8,856 shares of the medical research company’s stock, valued at approximately $693,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in EW. Quantbot Technologies LP purchased a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $26,000. SouthState Corp purchased a new stake in Edwards Lifesciences in the first quarter valued at approximately $27,000. Global X Japan Co. Ltd. raised its stake in Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 216 shares in the last quarter. Tradewinds Capital Management LLC raised its stake in Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 205 shares in the last quarter. Finally, Rossby Financial LCC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter valued at $29,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In related news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Up 0.5%

Shares of NYSE:EW opened at $77.03 on Friday. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The company has a market cap of $45.22 billion, a PE ratio of 11.08, a P/E/G ratio of 3.69 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The stock’s 50-day moving average is $78.50 and its 200 day moving average is $75.94.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the previous year, the firm earned $0.70 earnings per share. The business’s revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on EW. Royal Bank Of Canada raised their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Evercore ISI lifted their target price on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the stock an “in-line” rating in a research report on Friday, July 25th. BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Tuesday, July 29th. Finally, Canaccord Genuity Group lifted their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $86.61.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.